Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Cancer Research

• Publication date

  2009-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/0008-5472.CAN-08-4252PMID 19549911
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells

  2009cited by this paper
• Fostamatinib Disodium (FosD), An Oral Inhibitor of Syk, Is Well-Tolerated and Has Significant Clinical Activity in Diffuse Large B Cell Lymphoma (DLBCL) and Chronic Lymphocytic Leukemia (SLL/CLL)

  2008cited by this paper
• The kinase Syk as an adaptor controlling sustained calcium signalling and B‐cell development

  2008cited by this paper
• Specific Inhibition of Syk Is Sufficient to Disrupt Proliferation and Survival of Non-Hodgkin’s Lymphoma Cell Lines without Concomitant Inhibition of JAK.

  2008cited by this paper
• SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma.

  2008influential reference
• The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes.

  2008cited by this paper
• Rapid quantification of hepatitis B virus DNA by direct real-time PCR from serum without DNA extraction.

  2007cited by this paper
• Spleen Tyrosine Kinase (Syk), a Novel Target of Curcumin, Is Required for B Lymphoma Growth1

  2007cited by this paper
• Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.

  2007cited by this paper
• Correlation of ZAP-70 expression in B cell leukemias to the ex vivo response to a combination of fludarabine/genistein

  2007cited by this paper
• Emerging therapy for chronic lymphocytic leukaemia

  2007cited by this paper
• Temporal genetic program following B-cell receptor cross-linking: altered balance between proliferation and death in healthy and malignant B cells.

  2007cited by this paper
• Preclinical assessment of curcumin as a potential therapy for B‐CLL

  2007cited by this paper
• Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells.

  2006cited by this paper
• The real-time polymerase chain reaction.

  2006cited by this paper
• Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma

  2006cited by this paper
• Genomic and expression profiling identifies the B‐cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma

  2006cited by this paper
• R406, an Orally Available Spleen Tyrosine Kinase Inhibitor Blocks Fc Receptor Signaling and Reduces Immune Complex-Mediated Inflammation

  2006cited by this paper
• How I treat refractory CLL.

  2006cited by this paper
• B cells.

  2005cited by this paper
• Role of the STAT1 pathway in apoptosis induced by fludarabine and JAK kinase inhibitors in B-cell chronic lymphocytic leukemia

  2005cited by this paper
• Immunoglobulin gene segment usage, location and immunogenicity in mutated and unmutated chronic lymphocytic leukaemia

  2005cited by this paper
• Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells.

  2005cited by this paper
• Evidence for distinct pathomechanisms in genetic subgroups of chronic lymphocytic leukemia revealed by quantitative expression analysis of cell cycle, activation, and apoptosis-associated genes.

  2005cited by this paper
• ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia.

  2005cited by this paper
• B-cell receptor translocation to lipid rafts and associated signaling differ between prognostically important subgroups of chronic lymphocytic leukemia.

  2005cited by this paper
• Syk tyrosine kinase participates in beta1-integrin signaling and inflammatory responses in airway epithelial cells.

  2005cited by this paper
• Chronic lymphocytic leukemia: revelations from the B-cell receptor.

  2004cited by this paper
• Multiple Distinct Sets of Stereotyped Antigen Receptors Indicate a Role for Antigen in Promoting Chronic Lymphocytic Leukemia

  2004cited by this paper
• Chronic lymphocytic leukemia : revelations from the B-cell receptor

  2004cited by this paper
• ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia.

  2004cited by this paper
• A Model-Based Background Adjustment for Oligonucleotide Expression Arrays

  2004cited by this paper
• Leukotriene B4 plays a pivotal role in CD40-dependent activation of chronic B lymphocytic leukemia cells.

  2004cited by this paper
• Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia.

  2003cited by this paper
• B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor.

  2003cited by this paper
• Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia.

  2002cited by this paper
• B Cell Antigen Receptor Signaling: Roles in Cell Development and Disease

  2002cited by this paper
• Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia.

  2001cited by this paper
• Constitutive kinase activation of the TEL-Syk fusion gene in myelodysplastic syndrome with t(9;12)(q22;p12).

  2001cited by this paper
• Piceatannol, a hydroxylated analog of the chemopreventive agent resveratrol, is a potent inducer of apoptosis in the lymphoma cell line BJAB and in primary, leukemic lymphoblasts

  2001cited by this paper
• Biochemical Analysis of Activated T Lymphocytes

  2000cited by this paper
• Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.

  2000cited by this paper
• Tyrosine kinase SYK: essential functions for immunoreceptor signalling.

  2000influential reference
• Biochemical analysis of activated T lymphocytes. Protein phosphorylation and Ras, ERK, and JNK activation.

  2000cited by this paper
• Bryostatin and CD40‐ligand enhance apoptosis resistance and induce expression of cell survival genes in B‐cell chronic lymphocytic leukaemia

  1999cited by this paper
• Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.

  1999cited by this paper
• Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.

  1999cited by this paper
• Triggering of CD40 antigen inhibits fludarabine-induced apoptosis in B chronic lymphocytic leukemia cells.

  1998cited by this paper
• B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues.

  1997cited by this paper
• Normal Syk protein level but abnormal tyrosine phosphorylation in B-CLL cells

  1997cited by this paper
• Syk deficiency--a knockout for B-cell development.

  1996cited by this paper
• Prognostic factors and clinical staging in chronic lymphocytic leukemia.

  1990cited by this paper
• A clinical staging system for chronic lymphocytic leukemia. Prognostic significance

  1977cited by this paper

• Chemical synthesis of novel aminopyrimidin-4-yl-1H-pyrazole derivatives as spleen tyrosine kinase (SYK) inhibitors.

  2026cites this paper
• Visomitin as a differentiation-inducing therapeutic agent through SYK inhibition in AML

  2026cites this paper
• Differential regulatory effects of the N-terminal region in SYK-fusion kinases reveal unique activation-inducible nuclear translocation of ITK-SYK

  2025cites this paper
• Myeloid and Lymphoid Malignancies with Fusion Kinases Involving Spleen Tyrosine Kinase (SYK)—Emerging Rare Entities?

  2025cites this paper
• Integrative machine learning and structure-based drug repurposing for identifying potent inhibitors of human SYK activity against cancer.

  2025cites this paper
• Targeting the B cell receptor signaling pathway in chronic lymphocytic leukemia.

  2024cites this paper
• B cell receptor signaling proteins as biomarkers for progression of CLL requiring first-line therapy

  2024cites this paper
• Mutational landscape induced by chronic exposure to environmental PM10 and PM2.5 in A549 lung epithelial cell.

  2024cites this paper
• Spleen tyrosine kinase (SYK): an emerging target for the assemblage of small molecule antitumor agents

  2024cites this paper
• JNK1 inhibitors target distal B cell receptor signaling and overcome BTK-inhibitor resistance in CLL

  2024cites this paper
• Multiple omics levels of chronic lymphocytic leukemia

  2024cites this paper
• Promises of Protein Kinase Inhibitors in Recalcitrant Small-Cell Lung Cancer: Recent Scenario and Future Possibilities

  2024cites this paper
• B cell receptor signaling and associated pathways in the pathogenesis of chronic lymphocytic leukemia

  2024cites this paper
• CD38/NAD+ glycohydrolase and associated antigens in chronic lymphocytic leukaemia: from interconnected signalling pathways to therapeutic strategies.

  2024cites this paper
• Curcumin as a Natural Modulator of B Lymphocytes: Evidence from In Vitro and In Vivo Studies.

  2022cites this paper
• Platelets and tyrosine kinase inhibitors: clinical features, mechanism of action and effects on physiology.

  2022cites this paper
• Targeting the splicing isoforms of spleen tyrosine kinase affects the viability of colorectal cancer cells

  2022cites this paper
• Heterogeneity of Patient-Derived Acute Myeloid Leukemia Cells Subjected to SYK In Vitro Inhibition

  2022cites this paper
• Proapoptotic and immunomodulatory effects of SYK inhibitor entospletinib in combination with obinutuzumab in patients with chronic lymphocytic leukaemia

  2021cites this paper
• A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions

  2021cites this paper
• Characterizing the structure–activity relationships of natural products, tanshinones, reveals their mode of action in inhibiting spleen tyrosine kinase

  2021cites this paper
• Barriers to achieving a cure in lymphoma

  2021cites this paper
• Precursor B-ALL Cell Lines Differentially Respond to SYK Inhibition by Entospletinib

  2021influential citation
• Comparison of SYK Signaling Networks Reveals the Potential Molecular Determinants of Its Tumor-Promoting and Suppressing Functions

  2021cites this paper
• Protein Tyrosine Kinases: Their Roles and Their Targeting in Leukemia

  2021cites this paper
• Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell Lymphomas

  2020cites this paper
• Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma

  2020cites this paper
• Inhibition of the deubiquitinase USP10 induces degradation of SYK

  2020cites this paper
• HSP90 overexpression potentiates the B-cell receptor and fibroblast growth factor receptor survival signals in chronic lymphocytic leukemia cells

  2020influential citation
• Birth Order, Sibship Size, Childhood Environment and Immune-Related Disorders, and Risk of Lymphoma in Lymphoid Cancer Families

  2020cites this paper
• Fostamatinib Disodium.

  2020cites this paper
• Classic and Novel Signaling Pathways Involved in Cancer: Targeting the NF-κB and Syk Signaling Pathways.

  2019cites this paper
• Signal Transduction Pathways in Chronic Lymphocytic Leukemia

  2019cites this paper
• Beyond TCR Signaling: Emerging Functions of Lck in Cancer and Immunotherapy

  2019cites this paper
• Novel Inflammatory Mediators in Neuroblastoma Tumorigenesis

  2019cites this paper
• SYK Inhibition Potentiates the Effect of Chemotherapeutic Drugs on Neuroblastoma Cells In Vitro

  2019cites this paper
• Protein-Dysregulationen in humanen und murinen myeloproliferativen Neoplasien

  2018cites this paper
• Results of Multitarget Therapy Anti-PD-1/PD-L1/CD19/CD25/CD38 with Application of MSC-428 Molecules in Patients with Different Oncopathology

  2018cites this paper
• Crystal Structures of Spleen Tyrosine Kinase in Complex with Two Novel 4-Aminopyrido[4,3-d] Pyrimidine Derivative Inhibitors

  2018cites this paper
• Paper de la via de senyalització del receptor de cèl·lules B (BCR) en la interacció entre les cèl·lules de leucèmia limfàtica crònica i el microambient tumoral

  2018cites this paper
• Analysis of gene expression profiling variations induced by hsa-miR-145-5p-overexpression in laryngeal squamous cell carcinoma cell line Tu-177

  2017cites this paper
• Comparison of the mRNA expression profile of B‐cell receptor components in normal CD5‐high B‐lymphocytes and chronic lymphocytic leukemia: a key role of ZAP70

  2017cites this paper
• Innovative targeted therapies for chemorefractory B-cell non-Hodgkin lymphomas

  2017cites this paper
• Role of Protein Kinases and Their Inhibitors in Radiation Response of Tumor Cells.

  2017cites this paper
• Activity of the novel BCR kinase inhibitor IQS019 in preclinical models of B-cell non-Hodgkin lymphoma

  2017cites this paper
• Lck is a relevant target in chronic lymphocytic leukaemia cells whose expression variance is unrelated to disease outcome

  2017cites this paper
• Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase

  2017cites this paper
• Activated spleen tyrosine kinase promotes malignant progression of oral squamous cell carcinoma via mTOR/S6 signaling pathway in an ERK1/2-independent manner

  2017cites this paper
• High SYK Expression Drives Constitutive Activation of CD21low B Cells

  2017cites this paper
• Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase.

  2017cites this paper
• The kinase inhibitors R406 and GS-9973 impair T cell functions and macrophage-mediated anti-tumor activity of rituximab in chronic lymphocytic leukemia patients

  2017cites this paper
• Identification of distinct molecular subtypes of uterine carcinosarcoma

  2017cites this paper
• Régulation de l'activation de lymphocytes B / cellules plasmatiques pendant le rejet chronique : Le rôle de SYK dans la modulation de Mcl-1

  2017cites this paper
• Syk inhibitors in clinical development for hematological malignancies

  2017cites this paper
• Les lymphomes B diffus à grandes cellules de type activé : rôle de NF-κB et c-Myc.

  2017cites this paper
• Microenvironmental stromal cells abrogate NF-κB inhibitor-induced apoptosis in chronic lymphocytic leukemia

  2017cites this paper
• Spotlight on midostaurin in the treatment of FLT3-mutated acute myeloid leukemia and systemic mastocytosis: design, development, and potential place in therapy

  2017cites this paper
• Targeting B Cell Signaling in Chronic Lymphocytic Leukemia

  2017cites this paper
• Cell lines generated from a chronic lymphocytic leukemia mouse model exhibit constitutive Btk and Akt signaling

  2017cites this paper
• Curcumin in chronic lymphocytic leukemia – A review

  2017cites this paper
• ER maleate is a novel anticancer agent in oral cancer: implications for cancer therapy

  2016cites this paper
• Modulation of B-cell receptor and microenvironment signaling by a guanine exchange factor in B-cell malignancies

  2016cites this paper
• Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells

  2016cites this paper
• Spleen Tyrosine Kinase Is Involved in the CD38 Signal Transduction Pathway in Chronic Lymphocytic Leukemia

  2016cites this paper
• NF-κB activation in chronic lymphocytic leukemia: A point of convergence of external triggers and intrinsic lesions.

  2016cites this paper
• Crystal structures of spleen tyrosine kinase in complex with novel inhibitors: structural insights for design of anticancer drugs

  2016cites this paper
• From CLL to Multiple Myeloma ‐ Spleen Tyrosine Kinase (SYK) influences multiple myeloma cell survival and migration

  2016cites this paper
• Evolving Strategies for the Treatment of Chronic Lymphocytic Leukemia in the Upfront Setting

  2016cites this paper
• B cell receptor inhibition as a target for CLL therapy.

  2016cites this paper
• Five-Year Experience with Single-Agent Ibrutinib in Patients with Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia

  2016cites this paper
• Targeting Signaling Pathways in Chronic Lymphocytic Leukemia.

  2016cites this paper
• GZD824 suppresses the growth of human B cell precursor acute lymphoblastic leukemia cells by inhibiting the SRC kinase and PI3K/AKT pathways

  2016cites this paper
• SLP76 integrates into the B-cell receptor signaling cascade in chronic lymphocytic leukemia cells and is associated with an aggressive disease course

  2016cites this paper
• Targeting B-cell receptor signaling kinases in chronic lymphocytic leukemia: the promise of entospletinib

  2016influential citation
• De novo annotation of non-model organisms using whole genome and transcriptome shotgun sequencing

  2016cites this paper
• Best Practice & Research Clinical Haematology

  2016cites this paper
• Promising therapies for the treatment of chronic lymphocytic leukemia

  2015influential citation
• CD47 Agonist Peptides Induce Programmed Cell Death in Refractory Chronic Lymphocytic Leukemia B Cells via PLCγ1 Activation: Evidence from Mice and Humans

  2015cites this paper
• New Treatment Perspectives in CLL : Using Disease and Patient Characteristics to Optimize Outcomes

  2015cites this paper
• RPPA-based protein profiling reveals eIF4G overexpression and 4E-BP1 serine 65 phosphorylation as molecular events that correspond with a pro-survival phenotype in chronic lymphocytic leukemia

  2015cites this paper
• Role of Syk in the regulation of cytoskeleton and stress granules in breast cancer

  2015cites this paper
• Apoptosis Pathways in Chronic Lymphocytic Leukemia: Role of the Microenvironment and Therapeutic Strategies

  2015cites this paper
• Processing of CD74 by the intramembrane protease SPPL2a in B cells : Impact on endosomal trafficking and signaling

  2015cites this paper
• The tumor microenvironment shapes hallmarks of mature B-cell malignancies

  2015cites this paper
• Die Signaltransduktion der Fusionstyrosinkinase ITK-SYK im Rahmen der Lymphomentstehung

  2015cites this paper
• Calling in SYK: SYK's dual role as a tumor promoter and tumor suppressor in cancer.

  2015cites this paper
• The function of a novel immunophenotype candidate molecule PD-1 in chronic lymphocytic leukemia

  2015cites this paper
• Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.

  2015cites this paper
• Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules.

  2015cites this paper
• Inhibitors of BCR signalling interrupt the survival signal mediated by the micro‐environment in mantle cell lymphoma

  2015cites this paper
• Etudes des altérations fonctionnelles de la signalisation dépendante du récepteur à l’antigène dans les cellules B de la Leucémie Lymphoïde Chronique

  2015cites this paper
• Molécules d'anticorps anti-psyk et leur utilisation pour la thérapie ciblée sur syk

  2015cites this paper
• Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib

  2015cites this paper
• Proliferation and Differentiation Programs of Developing B Cells

  2015cites this paper
• Analysis of the anti-proliferative and the pro-apoptotic efficacy of Syk inhibition in multiple myeloma

  2015cites this paper
• Microenvironmental Signals and Enhanced Leukemia Cells Is Impaired by Tumor Receptor-1 in Chronic Lymphocytic The Expression of Sphingosine-1 Phosphate

  2014cites this paper
• leukemia major molecular and clinical subdivision in chronic lymphocytic Transcriptome characterization by RNA sequencing identifies a Material

  2014cites this paper
• Does B Cell Receptor Signaling in Chronic Lymphocytic Leukaemia Cells Differ from That in Other B Cell Types?

  2014cites this paper
• Depletion of STAT5 blocks TEL–SYK-induced APMF-type leukemia with myelofibrosis and myelodysplasia in mice

  2014cites this paper
• Gefitinib targets ZAP-70-expressing chronic lymphocytic leukemia cells and inhibits B-cell receptor signaling

  2014influential citation